Palopegteriparatide Shows Sustained Renal Gains at 182 Weeks in China Phase 3 Trial
Start here
Visen Pharma has reported 182-week long-term data from the phase 3 PaTHway China trial of palopegteriparatide. The results show 95.6% of patients remained off conventional therapy, mean eGFR rose 13.6 mL/min/1.73 m² from baseline, and 75.7% of patients achieved an eGFR increase of at least 5 mL/min/1.73 m². The data mark the latest readout in the program's development in China. Questions that remain open include regulatory decisions, broader commercial availability, and how the long-term findings will translate into clinical practice for eligible patients.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- WeChatVisen Pharma Reports 182-Week PaTHway China Phase 3 Data for Palopegteriparatide
Visen Pharma reported 182-week long-term data from the phase 3 PaTHway China trial of palopegteriparatide. 95.6% of patients remained off conventional therapy, mean eGFR rose 13.6 mL/min/1.73 m² from baseline, and 75.7% of patients had an eGFR increase of at least 5 mL/min/1.73 m².
Coverage and heat for this story
Reports so far 1·Heat now 6·Peak heat 10 (Oct 20 00:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.